Loading...
Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy
INTRODUCTION: Drotrecogin alfa (activated) (DrotAA) is licensed in the United States and the European Union for the treatment of severe sepsis with multiple organ failure. Patients with severe sepsis on renal replacement therapy (RRT), who typically receive additional anticoagulation to prevent circ...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2008
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2646328/ https://ncbi.nlm.nih.gov/pubmed/19094233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc7163 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|